N-Acetylcysteine (NAC) Treatment

Phase 3Small molecule

TThe First Affiliated Hospital of Soochow University

N-Acetylcysteine (NAC) Treatment is one of 74 small molecule programs targeting Acute Liver Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

HepatitisActive, not recruiting

Thrombotic MicroangiopathyActive, not recruiting

Breast CancerRecruiting

Acute Liver FailurePreclinical

Active, not recruiting

HepatitisPhase 3

Active, not recruiting

Thrombotic MicroangiopathyPhase 2/Phase 3

Active, not recruiting

Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

N-Acetylcysteine (NAC) Treatment

TThe First Affiliated Hospital of Soochow University

Phase 3

1 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Avastin

Roche

Preclinical

4 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Thrombotic Microangiopathy

NCT07279610

Q1 2027

Phase 3Not yet recruiting

Hepatitis

NCT06956482

Q4 2027

Phase 2Recruiting

Breast Cancer

NCT07117630

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder, PTSD1 trial

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Completed·MMedical University of South Carolina·Phase 2·NCT02966873·182 enrolled

Parkinson's Disease1 trial

Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study

Completed·—·Phase 2·NCT07093944·42 enrolled

Hepatitis1 trial

PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis

Not yet recruiting·UUniversity Hospital, Lille·Phase 3·NCT06956482·477 enrolled

Acute Liver Failure1 trial

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

Active, not recruiting·LLahore General Hospital·N/A·NCT06872372·62 enrolled

Thrombotic Microangiopathy1 trial

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy

Active, not recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT07279610·44 enrolled

1 more indication

Breast Cancer1 trial

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Recruiting·FFudan University·Phase 2·NCT07117630·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for N-Acetylcysteine (NAC) Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-Acetylcysteine (NAC) Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-Acetylcysteine (NAC) Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe First Affiliated Hospital of Soochow University

N-Acetylcysteine (NAC) Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Post-Traumatic Stress Disorder, PTSD1 trial

Parkinson's Disease1 trial

Hepatitis1 trial

Acute Liver Failure1 trial

Thrombotic Microangiopathy1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News